Methadone Clinics in Philadelphia, PA

List Map

Name	Address	City
Northeast Treatment Behavior	2205 Bridge Street	Philadelphia
Hospital of the University of Pennsylvania – Cedar Avenue	501 South 54th St.	Philadelphia
The Consortium, Inc. – University City Recovery Center	451 S University Ave	Philadelphia
JEVS Achievement Through Counseling and Treatment ACT I	5820 Old York Road	Philadelphia
JEVS Achievement Through Counseling and Treatment ACT II	1745 N 4th Street	Philadelphia
Thomas Jefferson University Narcotic Addiction Rehab Program	NE Corner of South 21st Street and	Philadelphia
John F Kennedy Community Mental Health	907 North Broad Street	Philadelphia
Amha Inc	928 Market Street	Philadelphia
Methadone Clinic Philadelphia	1233 Locust St	Philadelphia
Soar Corporation Philadelphia	9150 Marshall St #2217	Philadelphia
Hamilton Treatment Services	3444 Quakerbridge Rd building 1a	Hamilton Square
Solid Rock Recovery, LLC	208 White Horse Pike Suite 3	Barrington
Aldie Foundation, Inc.	11 Welden Dr	Doylestown
Camden Treatment Associates	508 Atlantic Ave	Camden
ARS of New Castle	263 Quigley Blvd Suite 1A	New Castle
SOAR Corp	655 Louis Drive	Warminster Heights
Soar Corporation Levittown	7500 Bristol Pike	Levittown
Vineland Treatment Services	1051 W. Sherman Ave Bldg 4	Vineland
Trenton Healthcare Clinic	801 New York Ave	Trenton
Valley Forge Medical Center and Hospital	1033 West Germantown Pike	Norristown

Treatment for opioid use disorder in Philadelphia

Philadelphia carries the heaviest overdose burden in Pennsylvania, and it also has one of the most developed treatment and harm-reduction systems in the country. Methadone clinics, office-based buprenorphine prescribers, hospital-linked programs, and tele-MOUD services all operate here, and most accept Medical Assistance through Community Behavioral Health, the city’s behavioral health managed care organization for Medicaid recipients. The listings above show local providers in the city; the sections below cover what your options actually are, how to start, what coverage looks like, and where to get naloxone today.

Your medication options and where each one is provided

Methadone is a full opioid agonist that stops withdrawal and cravings. For opioid use disorder, it is dispensed only through a federally certified opioid treatment program (OTP), not a regular pharmacy. Most people start with daily visits and earn take-home doses as treatment becomes stable. Philadelphia has a long-standing concentration of OTPs across most sections of the city, and most accept Medical Assistance. Many OTPs in the city also offer buprenorphine, which is useful if you and your clinician want the option to switch medications without switching programs. For more on how clinic-based treatment is structured, see what a methadone clinic does.

Buprenorphine, including the brand Suboxone (buprenorphine combined with naloxone) and the extended-release monthly injection Sublocade, is a partial agonist with a ceiling effect that makes overdose on the medication alone less likely. Since 2023, any clinician with a standard DEA registration that includes Schedule III authority can prescribe buprenorphine in an office and have it filled at a pharmacy. How methadone and Suboxone compare goes deeper into the trade-offs.

Naltrexone, including the monthly Vivitrol injection, blocks opioids rather than activating them. It is not a controlled substance and can be prescribed by any licensed provider, but treatment can only start after you have been off opioids for a set period, which is hard to navigate from active fentanyl use without medical support.

How to start treatment in Philadelphia

Most Philadelphia OTPs schedule intake within a few days, and several hospital and academic programs offer same-day buprenorphine starts. Penn’s Center for Addiction Medicine and Policy (CAMP) offers same-day buprenorphine initiation regardless of insurance, including for justice-involved patients and pregnant or parenting people. Many emergency departments in the city now start buprenorphine in the ED and bridge you to ongoing care, a practice supported by Penn Medicine, Jefferson, and Temple.

The most important thing to know if you are using fentanyl: starting buprenorphine too soon after a dose can trigger precipitated withdrawal, which is sudden, severe withdrawal caused by the medication itself. Philadelphia’s drug supply is now heavily adulterated with xylazine and, more recently, medetomidine, both of which lengthen and worsen withdrawal. Clinicians in the city have adjusted their induction protocols accordingly, often using lower starting doses, longer wait times, or microdosing. The right approach is to be honest with the intake nurse about what you have been using and when, so the timing is planned with you. See methadone treatment for fentanyl addiction for more on the methadone side of this decision.

Take-home doses and telehealth, current rules

Federal rules updated by SAMHSA in 2024 expanded take-home methadone (up to a 28-day supply for patients who are stable in treatment), allowed treatment to start by telehealth, and removed older barriers to admission such as the prior one-year-of-addiction requirement. Take-home eligibility is decided by the program based on your stability in treatment, not your zip code. Methadone for opioid use disorder remains an OTP medication; nothing in current law lets you pick it up at a retail pharmacy. Long-term methadone treatment covers what stable maintenance looks like over time.

For buprenorphine, telehealth flexibilities allowing initiation by phone or video without a prior in-person visit have been extended through December 31, 2026 by DEA and HHS. These rules are still being finalized, so confirm current options with whichever provider you reach.

Paying for treatment

Pennsylvania Medical Assistance, the state’s Medicaid program, covers all three FDA-approved medications for opioid use disorder. In Philadelphia, drug and alcohol services for Medicaid members are managed through Community Behavioral Health (CBH), a nonprofit behavioral health managed care organization contracted by the city and overseen by the Department of Behavioral Health and Intellectual disAbility Services (DBHIDS). CBH covers outpatient methadone and buprenorphine treatment, residential and inpatient care, and counseling, and most Philadelphia OTPs and office-based providers are in network.

Most major commercial insurers in the region cover MOUD, though specific cost-sharing and prior-authorization rules vary by plan. Medicare Part B covers OTP services, and Part D plans cover buprenorphine. Several Philadelphia providers see uninsured patients on sliding-scale fees and connect them to Medical Assistance enrollment at intake; ask about this when you call.

The Philadelphia overdose picture

The Philadelphia Department of Public Health recorded 1,069 unintentional overdose deaths in the city in 2024, an 18 percent decrease from 2023 and 24 percent below the 2022 peak. Fentanyl or fentanyl analogs were detected in 93 percent of opioid-involved deaths. Xylazine, a veterinary sedative now common in the local fentanyl supply, was detected in 34 percent of all overdose deaths, and medetomidine, an even more potent veterinary sedative the city began testing for in May 2024, was detected in 9 percent. Half of all overdose deaths in 2024 involved both opioids and stimulants, most often fentanyl with cocaine.

The decline is real but uneven. Overdose deaths among Non-Hispanic Black Philadelphians dropped 27 percent from 2023 to 2024, while overdoses among Hispanic Philadelphians have continued to rise. Kensington and surrounding North Philadelphia zip codes remain the highest-burden areas, but the crisis is citywide and most fatal overdoses occur in homes, not on the street. For context on the broader condition, see opioid use disorder. The point of the local numbers is not to alarm; it is to make clear that effective, local treatment exists, that more people are surviving long enough to reach it, and that getting into care today changes your odds.

Overdose prevention and harm reduction in Philadelphia

Philadelphia has one of the strongest overdose-response infrastructures in the country, and you do not need to be in treatment to use it.

Naloxone, the medication that reverses an opioid overdose, is sold over the counter as Narcan and is also available free through several local channels. The Philadelphia Department of Public Health operates resource hubs across the city that give out free naloxone, fentanyl test strips, and xylazine test strips. Prevention Point Philadelphia, the city’s longest-running harm-reduction organization based in Kensington, distributes naloxone on a sliding-scale or no-cost basis and provides syringe services, wound care, and outreach. A 24-hour naloxone vending machine is installed at the Lucien Blackwell Library in West Philadelphia. PDPH distributed more than 100,000 doses of naloxone in 2023 alone, and city officials credit wider naloxone access as a major reason fatal overdoses have declined. NEXT Distro mails naloxone for free to any Pennsylvania address after a short online training, with no insurance required. The Pennsylvania Department of Drug and Alcohol Programs also distributes free naloxone and test strips statewide. Recognizing and responding to an opioid overdose covers the basics of how naloxone is used.

Pennsylvania’s Good Samaritan provision, part of Act 139 of 2014, gives people who call 911 to report an overdose immunity from prosecution for simple drug possession and paraphernalia charges, as long as they stay with the person until help arrives, give their name, and cooperate with responders. The person who overdosed gets the same protection. If you witness an overdose, call 911 first.

A return to use is part of how opioid use disorder behaves for many people, and the response that works is to come back, adjust the medication or dose, and keep going.

Specific situations: pregnancy, justice-involved care, and Kensington

For pregnant people with opioid use disorder, methadone and buprenorphine are the recommended standard of care in pregnancy, supported by SAMHSA and ACOG. Untreated opioid use during pregnancy carries far greater risk than medication treatment. Neonatal opioid withdrawal syndrome (NOWS) can occur but is treatable and is not a reason to avoid medication. Penn’s CAMP program offers integrated perinatal substance-use care, and several Philadelphia OBGYN and family medicine practices coordinate prenatal care with MOUD. Pennsylvania uses Plans of Safe Care to coordinate care for infants exposed to substances, and treatment with MOUD during pregnancy is protective, not a basis for child-welfare involvement on its own. For more, see methadone and pregnancy.

For people leaving Philadelphia Department of Prisons facilities or PA state correctional institutions, the period right after release is the highest-risk window for fatal overdose because tolerance drops during incarceration. Continuity of MOUD into the community is the protective factor. The Pennsylvania Institutional Law Project has documented serious gaps in MOUD access across PA county jails, and the city’s reentry coordinators and several treatment programs work with people scheduled for release. If you or someone you care about is approaching release, calling a community provider before the release date to schedule intake is the single most useful step. Information for families covers how loved ones can help.

For people in Kensington and surrounding neighborhoods, where the open drug market and the heaviest fentanyl-xylazine adulteration are concentrated, low-barrier care is the priority. Same-day buprenorphine starts, mobile and street-medicine teams, and wound care for xylazine-related skin injuries are part of the local clinical response. Honesty with the intake clinician about what you have been using is what lets them plan an induction that does not trigger precipitated withdrawal.

Common questions

Is Suboxone better than methadone, or the other way around?

Both are first-line treatments and both reduce the risk of overdose death by about half compared to no medication. Methadone is more potent and more structured, with daily clinic visits early in treatment; it tends to work well for people with severe, long-standing opioid use, including heavy fentanyl use. Buprenorphine is partial-agonist, has a lower ceiling on respiratory depression, and is generally more flexible because it can be prescribed in an office. The right choice depends on your medical history, what you have used, your work and family life, and what you and a clinician decide together.

Do I have to go to the clinic every day forever?

No. Federal rules now allow up to a 28-day supply of take-home methadone for patients who are stable in treatment, and most Philadelphia OTPs use a graduated schedule that increases take-homes as stability builds. Why staying on your dose matters covers the trade-off.

Can I start buprenorphine without ever going in person?

Often, yes. Through 2026, federal telehealth rules allow buprenorphine to be started by video or by phone in many cases without a prior in-person visit, subject to your provider’s protocols and Pennsylvania law. Methadone induction can be started by audio-video telehealth within an OTP, but methadone is then dispensed in person at the clinic.

Will using methadone or Suboxone show up on a job or custody case?

MOUD is legitimate prescribed medical treatment, and federal and state laws give specific protections against discrimination for people in treatment. Your treatment records are protected by federal confidentiality rules (42 CFR Part 2). A drug screen for buprenorphine or methadone is interpreted in the context of your prescription. More common questions covers further details.

What if I have used methadone before and want to come back?

You can. Programs do not require you to start over from a moral position; restarting is common and is the right move. Bring whatever records you have, but do not let missing paperwork stop you from calling.

Sources and disclosures

Last reviewed June 2026.

Sources:

Philadelphia Department of Public Health, Unintentional Drug Overdose Fatalities in Philadelphia, 2024 (April 2026).
Substance Abuse and Mental Health Services Administration (SAMHSA), 42 CFR Part 8 final rule, 2024.
DEA and HHS, Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications, Federal Register, December 31, 2025.
DEA and HHS, Expansion of Buprenorphine Treatment via Telemedicine Encounter, final rule effective December 31, 2025.
Pennsylvania Department of Human Services, Behavioral HealthChoices program.
City of Philadelphia, Department of Behavioral Health and Intellectual disAbility Services (DBHIDS) and Community Behavioral Health (CBH).
Pennsylvania Department of Drug and Alcohol Programs, Overdose Prevention Program and statewide naloxone standing order.
Act 139 of 2014 (Pennsylvania Good Samaritan / David’s Law).
Pennsylvania Institutional Law Project, Medication for Opioid Use Disorder in Pennsylvania Jails and Prisons.

Methadone Centers is not a medical provider and does not deliver clinical care. The information on this page is for general education and does not replace evaluation, diagnosis, or treatment by a licensed clinician.

Calls to the helpline displayed on this site may be answered by a paid sponsor. This site receives compensation for some of the listings and helpline referrals shown.

Methadone Clinics in Philadelphia, Pennsylvania

Call For Help With Addiction

Talk To Someone Now

No results found!